{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T16:26:25Z","timestamp":1764951985916,"version":"3.46.0"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cancer Policy"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jcpo.2025.100655","type":"journal-article","created":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T17:11:59Z","timestamp":1761412319000},"page":"100655","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Investigational sites requirements according to trial complexity and intervention level under EU Regulation No. 536\/2014"],"prefix":"10.1016","volume":"46","author":[{"given":"Celeste","family":"Cagnazzo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evaristo","family":"Maiello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Labianca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2210-5469","authenticated-orcid":false,"given":"Valeria","family":"Facciolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Perrone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gennaro","family":"Daniele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Di Maio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmine","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcpo.2025.100655_bib1","first-page":"1","article-title":"Council of the European Union, Regulation (EU) No 536\/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001\/20\/EC","volume":"158","author":"European Parliament","year":"2014","journal-title":"Off. J. Eur. Union L"},{"issue":"5","key":"10.1016\/j.jcpo.2025.100655_bib2","first-page":"299","article-title":"[Implementation of European Regulation 536\/2014 in Italy: the never-ending story]","volume":"113","author":"Cagnazzo","year":"2022","journal-title":"Recent Prog. Med"},{"issue":"31","key":"10.1016\/j.jcpo.2025.100655_bib3","doi-asserted-by":"crossref","first-page":"3796","DOI":"10.1200\/JCO.2016.69.6781","article-title":"Addressing administrative and regulatory burden in cancer clinical trials: summary of a stakeholder survey and workshop hosted by the American Society of Clinical Oncology and the Association of American Cancer Institutes","volume":"34","author":"Vase","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.jcpo.2025.100655_bib4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.5301\/tj.5000668","article-title":"New requirements for phase I trials: a challenge for Italian clinical research","volume":"104","author":"Marchesi","year":"2018","journal-title":"Tumor J."},{"issue":"4","key":"10.1016\/j.jcpo.2025.100655_bib5","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1177\/0300891619868008","article-title":"Phase I studies: a test bench for Italian clinical research","volume":"106","author":"Cagnazzo","year":"2020","journal-title":"Tumor J."},{"key":"10.1016\/j.jcpo.2025.100655_bib6","doi-asserted-by":"crossref","DOI":"10.2427\/10246","article-title":"Towards a more competitive Italy in clinical research: the survey of attitudes towards trial sites in Europe (The SAT-EU Study\u2122)","author":"Gehring","year":"2022","journal-title":"Epidemiol. Biostat. Public Health 121"},{"year":"2024","series-title":"Clinical trials of medicinal products in Italy \u2013 21st National Report 2024","author":"Italian Medicines Agency (AIFA)","key":"10.1016\/j.jcpo.2025.100655_bib7"},{"key":"10.1016\/j.jcpo.2025.100655_bib8","unstructured":"Italian Ministry of Health, Measures to facilitate and support the conduct of non-profit clinical trials and observational studies, and to regulate the transfer of data and results from non-profit trials for registration purposes, pursuant to Legislative Decree of 14 May 2019, Article 1(c), Official Gazette of the Italian Republic, 19 February 2022."},{"key":"10.1016\/j.jcpo.2025.100655_bib9","unstructured":"Spanish Agency of Medicines and Medical Devices (Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios \u2013 AEMPS), Royal Decree 1090\/2015 of 4 December regulating clinical trials with medicinal products, Ethics Committees for investigation with medicinal products and the Spanish Clinical Studies Registry, Bolet\u00edn Oficial del Estado 307 (2015). \u3008https:\/\/www.aemps.gob.es\/legislacion\/espana\/investigacionClinica\/docs\/Royal-Decree-1090\u3009- 2015_4-December.pdf."},{"key":"10.1016\/j.jcpo.2025.100655_bib10","unstructured":"Spanish Agency of Medicines and Medical Devices (Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios \u2013 AEMPS). Common specific criteria for the accreditation, inspection and renewal of the accreditations of Ethics Committees for Research with Medicinal Products (CEIm) [Internet], Madrid, Spain, 2022. \u3008https:\/\/www.aemps.gob.es\u3009."},{"key":"10.1016\/j.jcpo.2025.100655_bib11","unstructured":"Central Committee on Research Involving Human Subjects (CCMO), Suitability of the facilities, CCMO, The Hague, 2023. \u3008https:\/\/english.ccmo.nl\/investigators\/clinical-trials-with-medicinal-products-ctr\/preparation-ctr\/research-dossier-part-ii\/suitability-of-the-facilities\u3009."},{"key":"10.1016\/j.jcpo.2025.100655_bib12","unstructured":"Ministry of Solidarity and Health, Decree No. 2022-323 of 4 March 2022 relating to research involving the human person and to clinical trials of medicinal products, Official Journal of the French Republic, 4 March 2022, 39. \u3008https:\/\/www.legifrance.gouv.fr\/jorf\/id\/JORFTEXT000045317824\u3009."},{"key":"10.1016\/j.jcpo.2025.100655_bib13","unstructured":"Health Research Authority (HRA), HRA Approval, HRA, London, 2025. \u3008https:\/\/www.hra.nhs.uk\/approvals-amendments\/what-approvals-do-i-need\/hra-approval\/\u3009."},{"key":"10.1016\/j.jcpo.2025.100655_bib14","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1186\/s13063-019-3790-9","article-title":"Criteria for site selection in industry-sponsored clinical trials: a survey among decision-makers in biopharmaceutical companies and clinical research organizations","volume":"20","author":"Dombernowsky","year":"2019","journal-title":"Trials"},{"key":"10.1016\/j.jcpo.2025.100655_bib15","unstructured":"Italian Medicines Agency (AIFA), Determination concerning the minimum requirements for healthcare facilities conducting phase I clinical trials pursuant to Article 11 of Presidential Decree 439\/2001 and Article 31(3) of Legislative Decree 200\/2007, 10 July 2015. \u3008https:\/\/www.gazzettaufficiale.it\/atto\/serie_generale\/caricaDettaglioAtto\/originario?atto.dataPubblicazioneGazzetta=2015-07-10&atto.codiceRedazionale=15A05315\u3009."},{"year":"2020","series-title":"Clinical trials of medicinal products in Italy \u2013 19th National Report 2020","author":"Italian Medicines Agency (AIFA)","key":"10.1016\/j.jcpo.2025.100655_bib16"},{"key":"10.1016\/j.jcpo.2025.100655_bib17","unstructured":"Italian Medicines Agency (AIFA), Determination concerning the self-certification of the minimum requirements of healthcare facilities conducting phase I clinical trials pursuant to Article 3, paragraphs 1 and 2, of the AIFA Director General\u2019s Determination of 19 June 2015, 29 March 2016."},{"year":"2023","series-title":"Clinical trials of medicinal products in Italy \u2013 20th National Report 2023","author":"Italian Medicines Agency (AIFA)","key":"10.1016\/j.jcpo.2025.100655_bib18"},{"key":"10.1016\/j.jcpo.2025.100655_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1661186","article-title":"Tracking a decade of phase I clinical trials in Italy: trends and insights from national and European registries amid regulatory change","volume":"16","author":"De Paola","year":"2025","journal-title":"Front. Pharm."}],"container-title":["Journal of Cancer Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213538325000992?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213538325000992?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T16:21:38Z","timestamp":1764951698000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213538325000992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":19,"alternative-id":["S2213538325000992"],"URL":"https:\/\/doi.org\/10.1016\/j.jcpo.2025.100655","relation":{},"ISSN":["2213-5383"],"issn-type":[{"type":"print","value":"2213-5383"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Investigational sites requirements according to trial complexity and intervention level under EU Regulation No. 536\/2014","name":"articletitle","label":"Article Title"},{"value":"Journal of Cancer Policy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcpo.2025.100655","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100655"}}